New Vida Health Study Reports Real-World Obesity Care Outcomes Across More Than 10,000 Adults

Vida Health, a leading digital health company delivering integrated, longitudinal cardiometabolic and behavioral health care, announced results from a real-world analysis of its total enrolled population, not a narrow or high-acuity subset. Presented at ObesityWeek 2026, the analysis of more than 10,000 adults across 30 employer organizations captures outcomes across a broad range of members and treatment experiences rather than a selected subset of patients. The study found an average of 7.3% weight loss at 12 months across all members, and results were meaningful in each of the three treatment cohorts: new to GLP-1 therapy, transfer of GLP-1 care, and behavioral and non-GLP-1 medication.

Unlike trials that focus on high-acuity cohorts or have high BMI thresholds, Vida’s real-world analysis included all members of the program. It looked at weight loss averages 12 months out from the day of enrollment rather than from the start of full dosage of GLP-1 medication. The results include members who started medication later in their course of treatment, titrated slowly, or paused medication, offering a more complete picture of the outcomes people experience as they navigate obesity care in the real world. The findings provide a clearer view of what employers and health plans can expect across a real workforce when obesity care is comprehensive and individualized.

“What’s important to know is that holistic obesity care can deliver meaningful improvements in health across an employer’s entire workforce. We don’t need to rely solely upon what a medication can achieve under ideal conditions,” said Richard Frank, MD, Chief Medical Officer at Vida Health. “These findings demonstrate that clinically meaningful outcomes are possible across different treatment pathways and stages of care. Having a clearer picture of results in a real-world population can help employers make more informed decisions about how to support members and manage the long-term costs of obesity.”

Key Findings

The retrospective analysis evaluated adults enrolled in Vida’s telehealth program between January 2024 and September 2025. Of the 10,019 adults included in the analysis, 4,944 had 12-month weight data and achieved an average total body weight loss of 7.3%. Results varied by cohort:

  • New to GLP-1 therapy: 10.0% average weight loss among members who initiated GLP-1 treatment through Vida (n=850)

  • Transfer of GLP-1 care: 8.0% average weight loss among members who transferred to Vida already taking a GLP-1 and continued GLP-1 therapy (n=2,112)

  • Behavioral and non-GLP-1 care: 5.5% average weight loss among members receiving behavioral care alone or alongside a non-GLP-1 medication (n=1,982)

Beyond weight loss, members also saw improvements in key cardiometabolic measures over 12 months, including:

  • 16.5 mg/dL reduction in triglycerides

  • 6.1 mg/dL reduction in total cholesterol

  • 5.2 mg/dL reduction in LDL “bad” cholesterol

  • 3.8 mg/dL reduction in glucose

  • 1.9 mg/dL increase in HDL “good” cholesterol

  • 0.21 percentage-point reduction in HbA1c

“Treating cardiometabolic health takes more than prescribing medication. It requires understanding the many factors that shape a person’s health and how their treatment evolves in daily life,” said Aarathi Venkatesan, PhD, SVP, Business Intelligence & Health Analytics and lead author of the study. “We designed our study to measure progress from the moment people entered care to capture the realities of treatment, including the time it takes to start and adjust medication therapies. We also looked beyond weight alone. Examining improvements in blood sugar and cholesterol alongside weight loss gives us a more complete picture of how treatment can affect a person’s overall cardiometabolic health.”

About Vida Health

Vida Health is a value-based, virtual cardiometabolic care provider that matches members to the right level of care based on their metabolic instability. Its medication guidance system prioritizes lower-cost, high-value therapeutic alternatives across obesity, diabetes, hypertension, hyperlipidemia, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea (OSA), and chronic obstructive pulmonary disease (COPD). Vida serves members at all acuity levels, combining evidence-based prescribing with behavior change support and provider-led care. The company’s multidisciplinary team of obesity medicine-certified physicians, nurses, registered dietitians, expert coaches, and licensed therapists delivers a whole-person approach that improves outcomes while reducing avoidable healthcare costs. Vida serves members in all 50 states and Washington, D.C., offers services in both English and Spanish, and operates on a value-based pricing model that centers on measurable health outcomes. To learn more, visit www.Vida.com.

Media gallery